Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601397 | 0.76 | KDM4E (0.34) | MEN1KMT2AHSP90AA1 | |
| SCHEMBL30128675 | 0.74 | CDK2 (0.38) | CDK2CHEK1CCNA2CCNA1KDR | |
| SCHEMBL30363736 | 0.72 | KDR (0.49) | CDK2CHEK1CCNA2CCNA1KDR | |
| SCHEMBL22601380 | 0.72 | CDK2 (0.34) | CDK2CCNA2GSK3BCCNE1 | |
| SCHEMBL22941455 | 0.70 | CDK2 (0.41) | CDK2CHEK1CCNA2CCNA1KDR | |
| SCHEMBL21266059 | 0.70 | ADORA2A (0.42) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL11931303 | 0.68 | CDK2 (0.56) | CDK2CHEK1CCNA2CCNA1KDR | |
| SCHEMBL11931286 | 0.66 | KDR (0.43) | CDK2CHEK1CCNA2CCNA1KDR | |
| SCHEMBL12954007 | 0.65 | CDK2 (0.52) | CDK2CHEK1CCNA2CCNA1KDR | |
| SCHEMBL28392486 | 0.64 | KDR (0.41) | CDK2CHEK1CCNA2CCNA1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CDK2 43/4885CHEK1 515/4885CCNA2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.